| Revenue growth | 10% YoY for Q4 FY26 excluding one-time items. |
|---|---|
| Margins | EBITDA margin 23% in Q4; improvement from favorable mix. |
| Demand visibility | Strong for biosimilars; ramp-up expected in H2 FY27. |
| Management confidence | High; integration complete, major investment phase behind us. |
Growth
Biosimilars grew 12%, Generics 13% (adj.), and EBITDA rose 25% YoY for FY26 with 22% margins.
Outlook
Guidance for progressive improvement in FY27 as new products like Aspart and Aflibercept scale in H2.
Risks
Geopolitical uncertainties impacting supply chains, logistics, and energy costs; competitive pricing in US medical benefit markets.
Earnings Call filed with BSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹382.15
- Market cap
- ₹62,279 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 125.7×Sector 50.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon Bags New Order from Bahiafarma and Bionovis
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
- From
- Bahiafarma and Bionovis (Brazil PDP program)
- Execution
- 10 years
Biocon Investor Presentation: Key Takeaways
Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.
Biocon Investor Presentation: Key Takeaways
Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.
Biocon Q1 FY27 Results: Net Profit ₹136.8 Cr, Up 53.4% YoY
Biocon Ltd reported revenue from operations of ₹4,336 Cr (+10.0% YoY) and net profit of ₹136.8 Cr (+53.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹136.8 Cr · +53.4% YoY
Biocon Earnings Call: Key Takeaways
Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.